

Press Release

Stockholm, Sweden, January 7, 2025

Mendus to participate in several investor and industry conferences in January

Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that it will participate in the following upcoming investor and industry conferences:

43rd Annual J.P. Morgan Healthcare Conference

San Francisco, USA, January 13-16, 2025

Mendus management team will be in San Francisco for business and investor meetings during the J.P. Morgan conference

14th Annual LifeSci Partners Corporate Access Event

San Francisco, USA, January 13-15, 2025

Mendus will take part in the LifeSci Corporate Access investor event

H.C. Wainwright & Co. during JPM 2025

San Francisco, USA, January 13-16, 2025

Mendus will attend the H.C. Wainwright conference and events during JPM

Redeye Theme: Fight Cancer

Stockholm, Sweden, January 22, 2025

Mendus CEO Erik Manting will present the company and take part in a discussion panel. For more information, please see

<https://www.redeye.se/events/1052608/redeye-theme-fight-cancer-3?tab=abouttheevent>

For more information, please contact:

Erik Manting

Chief Executive Officer

E-mail: ir@mendus.com

About Mendus AB (publ)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. <https://www.mendus.com/>